Background : Aiming to improve outcome of lung transplantation (LTx) patients, we reviewed risk factors and treatment practices for the LTx recipients who experienced respiratory infection in the late post-LTx period (>1 month after LTx). Materials and Methods : We analyzed the clinical data of 48 recipients and donors from 61 LTx, who experienced late respiratory infections. Late respiratory infections were classified according to the etiology, time of occurrence, and frequency of donor-to-host transmission or colonization of the recipient prior to transplantation. Results : During the period of observation, 42 episodes of respiratory infections occurred. The organisms most frequently involved were gram (−) bacteria: Acinetobacter ba...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
International audienceBACKGROUND:Respiratory infections are a major threat for lung recipients. We a...
Background: Multidrug-resistant (MDR) bacteria in the lower respiratory tracts of allografts may be ...
Lung transplant recipients are at greater risk of respiratory viral infections as compared to other ...
Purpose: Nontuberculous mycobacteria (NTM) infection is an important issue after lung transplantatio...
Current trends in the epidemiology, outcome and vari-ables influencing mortality in bacteremic lung ...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/71409/1/j.1600-6143.2006.01565.x.pd
Abstract Background Bacterial respiratory infections (BRI) are major complications contributing to i...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
Copyright © 2020. Published by Elsevier Inc. PURPOSE: This study assessed respiratory pathogens isol...
Introduction: We report on characteristics and lung function outcomes among lung transplant recipien...
(1) Background: Lung transplant recipients (LTRs) are at substantial risk of invasive fungal disease...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
International audienceBACKGROUND:Respiratory infections are a major threat for lung recipients. We a...
Background: Multidrug-resistant (MDR) bacteria in the lower respiratory tracts of allografts may be ...
Lung transplant recipients are at greater risk of respiratory viral infections as compared to other ...
Purpose: Nontuberculous mycobacteria (NTM) infection is an important issue after lung transplantatio...
Current trends in the epidemiology, outcome and vari-ables influencing mortality in bacteremic lung ...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/71409/1/j.1600-6143.2006.01565.x.pd
Abstract Background Bacterial respiratory infections (BRI) are major complications contributing to i...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
Copyright © 2020. Published by Elsevier Inc. PURPOSE: This study assessed respiratory pathogens isol...
Introduction: We report on characteristics and lung function outcomes among lung transplant recipien...
(1) Background: Lung transplant recipients (LTRs) are at substantial risk of invasive fungal disease...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...